Money
Nouscom Secures $135 Million for Cancer Prevention Vaccine Trials
Swiss biotech firm Nouscom has raised $135 million to advance its off-the-shelf cancer prevention vaccine for patients with Lynch syndrome.
October 19, 2026, 01:21 PM·Tech Funding News
